lingdolinurad

Lingdolinurad is a novel oral small molecule inhibitor of human uric acid transporter 1 (URAT1), developed by Atom Therapeutics (formerly Atom Bioscience) for the treatment of chronic gout and hyperuricemia. By inhibiting URAT1 (SLC22A12 protein), lingdolinurad reduces renal reabsorption of uric acid, thereby increasing its excretion and lowering serum uric acid levels. Clinical trials have demonstrated that it is safe and effective at multiple dose levels (from 1 mg to 12 mg), with a once-daily tablet formulation showing efficacy comparable to benzbromarone and febuxostat. Lingdolinurad is currently in late-stage clinical development globally for gout and hyperuricemia; it has also been studied in patients with renal failure[1][2][3][4][5][7][8].

Brand names

lingdolinurad

Other names

3-bromo-5-(2-ethylimidazo[1,2-a]pyridine-3-carbonyl)-2-hydroxybenzonitrile2088176-96-7